Fate Therapeutics Inc (NASDAQ: FATE) stock closed at $6.61 on 3/22/24 after a major decline of -11.0%. However, below average trading volume at 68% of normal accompanied the decline. The stock has declined -8.6% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
FATE is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Fate Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Fate Therapeutics has a poor Appreciation Score of 17 but a very high Power Rating of 94, and the Neutral Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment